Paper · 39796751
Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.
Gough R and 3 others. Cancers (Basel), 2025. Cited by 6 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging. Papers, record 39796751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796751
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References189
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,219,809 | Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma. | Semin Radiat Oncol | 2014 | https://conductscience.org/library/papers/25219809 | PubMed |
| 2 | 28,574,607 | Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. | Neuropathol Appl Neurobiol | 2018 | https://conductscience.org/library/papers/28574607 | PubMed |
| 3 | 30,627,060 | Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. | Contrast Media Mol Imaging | 2018 | https://conductscience.org/library/papers/30627060 | PubMed |
| 4 | 26,940,435 | Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. | Sci Rep | 2016 | https://conductscience.org/library/papers/26940435 | PubMed |
| 5 | 31,078,973 | Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/31078973 | PubMed |
| 6 | 28,298,040 | Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. | J Neurosurg | 2018 | https://conductscience.org/library/papers/28298040 | PubMed |
| 7 | 25,646,027 | Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/25646027 | PubMed |
| 8 | 34,610,950 | Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34610950 | PubMed |
| 9 | 38,548,655 | Utilizing the amide proton transfer technique to characterize diffuse gliomas based on the WHO 2021 classification of CNS tumors. | Neuroradiol J | 2024 | https://conductscience.org/library/papers/38548655 | PubMed |
| 10 | 25,865,896 | ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes. | Cell Rep | 2015 | https://conductscience.org/library/papers/25865896 | PubMed |
1 to 10 of 189
See all 189 referencesCited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,249,986 | Integrated CT-PET radiogenomics and graph-based multi-task learning for preoperative prediction of key glioma molecular markers. | Neuroradiology | 2026 | https://conductscience.org/library/papers/42249986 | PubMed |
| 42,004,686 | Plasma histone monomers as novel diagnostic markers in adult glioblastoma. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42004686 | PubMed |
| 41,566,316 | 18F-FDG PET imaging reveals GW4869's suppression of glioblastoma malignant progression and reversal of TMZ chemoresistance via glucose metabolic phenotype remodeling. | J Transl Med | 2026 | https://conductscience.org/library/papers/41566316 | PubMed |
| 41,400,876 | Progress in the Synthesis and Application of Phycocyanin-Based Nanoparticles. | Top Curr Chem (Cham) | 2025 | https://conductscience.org/library/papers/41400876 | PubMed |
| 40,751,888 | Towards non-invasive diagnosis of glioblastoma: identifying metabolic biomarkers in liquid biopsies using a ROC-based approach. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40751888 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796751
GET https://conductscience.org/api/papers/v1/39796751/references?page=2